Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.

Molecular cancer therapeutics - 1 Jan 2015

Liu Yang, Kwiatkowski David J

Abstract excerpt

Invasive bladder cancer has high morbidity and nearly uniform mortality when metastatic, with no therapeutic improvement in many years. Although chemotherapy combined with Chk1 inhibition has been investigated in several cancer types in which TP53 mutation is seen, this combination treatment approach has not been studied in bladder cancer. Recently, cancer genome sequencing efforts have identified CDKN1A (p21)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 1
Share to Cyclin-Dependent Kinase Inhibitor p21
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Gemcitabine

Share to Pyrazoles

Share to Thiophenes

Source

Open in PubMed Open full text

Identifiers

PMID: 25349305
DOI: 10.1158/1535-7163.MCT-14-0622-T
PMCID: PMC4297264

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.PMID 25349305Read ↗

Significance of TP53 mutation in bladder cancer disease progression and drug selectionSemantic proximity Read ↗

Tp53 and its potential therapeutic role as a target in bladder cancerSemantic proximity Read ↗

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read ↗

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.Semantic proximity Read ↗

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Semantic proximity Read ↗

Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.Semantic proximity Read ↗

Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients.Semantic proximity Read ↗

p53 and chemosensitivity in bladder cancer.Semantic proximity Read ↗

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.Semantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.